Since the pioneering studies, by Hancock et al. on heart transplantation [83], CXCL10 neutralization per se seems enough to improve cardiac function and counteract heart rejection; thereafter, the pivotal role of CXCL10 has been confirmed in human heart transplantation [78, 79, 84] and recognized in human cardiac function and diseases, from myocarditis to cardiac pulmonary bypass or coronary artery disease [85–87]. The gene discussed is CXCL10; the disease is coronary artery disorder.